WI Harper Group-backed EdiGene Raises ~USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage
[vc_row][vc_column][vc_column_text]WI Harper Group | October 14, 2020 | Source: Businesswire[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][/vc_column][/vc_row][vc_row][vc_column][vc_single_image source=”external_link” external_img_size=”500×250″ alignment=”center” custom_src=”https://wiharper.com/wp-content/uploads/2020/10/EG1.png”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]WI Harper Group backed EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, announced the…